In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

Only 13 states currently allow Medicaid to cover GLP-1 agonist drugs for obesity treatment, highlighting a significant gap in ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

News and talk of GLP-1 drugs are everywhere these days ... and what sometimes seems like an ever-growing list of other conditions the drugs could potentially treat. There are new headlines ...

Smoothie King is launching a new GLP-1 Support Menu specifically aimed at people using a GLP-1 agonist. The menu, which ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

It's also worth noting that ex-GLP 1 subgrowth would have been 40% y/y ... in August after the FDA removed semaglutide from ...